Clinical Trial Detail

NCT ID NCT03106779
Title Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Bosutinib

Asciminib

Age Groups: adult senior

Additional content available in CKB BOOST